Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Research & Development (R&D) Day  (Replay)
    Thursday, December 06, 2018 12:00 pm EST
Toggle Summary Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
PASADENA, Calif. & HOPKINTON, Mass.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory
Toggle Summary Spring Bank Pharmaceuticals Abstracts on STING Agonist SB 11285 Accepted for Poster Presentations at AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced that two abstracts related to SB
Toggle Summary Spring Bank Pharmaceuticals, Inc. to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13th, 2016
HOPKINTON, Mass. , Aug. 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced it will present at the 18 th
Toggle Summary Spring Bank Pharmaceuticals Announces Second Quarter 2016 Financial Results and Recent Highlights
HOPKINTON, Mass. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced second quarter 2016 financial
Toggle Summary Spring Bank Pharmaceuticals Appoints Dr. Todd C. Brady to its Board of Directors
Health Care Veteran Adds Significant Biopharmaceutical Development and Leadership Experience MILFORD, Mass. , July 28, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral
Toggle Summary Spring Bank Pharmaceuticals Added to Russell Microcap® Index
HOPKINTON, Mass. , June 27, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and cancer, announced that it was added to the Russell
Toggle Summary Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B (HBV) 
Phase 2a Study to Evaluate SB 9200 Monotherapy Followed By Sequential Dosing with VireadÒ in 80 Treatment-Naïve HBV Patients HOPKINTON, Mass. , June 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics
Toggle Summary Spring Bank Pharmaceuticals to Present at Upcoming Investor Conferences
MILFORD, Mass. , May 25, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that the Company will present at the following upcoming investor
Toggle Summary Spring Bank Pharmaceuticals Announces Closing of Initial Public Offering
MILFORD, Mass. , May 11, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the closing of its initial public offering of 920,000 shares of common
Toggle Summary UPDATE -- Spring Bank Pharmaceuticals Announces Pricing of Initial Public Offering
MILFORD, Mass. , May 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the pricing of its initial public offering of 920,000 shares of common stock at a